A strategy of selective approach for histopathological examination of gallbladder specimens may be safe in areas with very low incidence of gallbladder carcinoma. Such selective strategy is more cost-effective, reduces the workload of pathologists, and does not appear to compromise patient outcome.
Objective: Routine histopathological examination of all gallbladder specimens, regardless of the clinical characteristics of the patient or macroscopic aspect of the gallbladder, is the current approach to detect the presence of gallbladder carcinoma. The aim of the present study was to assess whether or not it would be safe to adopt a policy of processing only gallbladder specimens with preoperative or intraoperative suspicion for malignancy without compromising patient safety. Material and Methods: From January 2009 to June 2017, all histopathology reports of 3423 consecutive gallbladder specimens after elective and emergency cholecystectomies were retrospectively analyzed in two university hospitals. Results: A total of 3423 gallbladder specimens submitted for histopathological examination during the study period were included into the study. The results of histopathological examination of these gallbladder specimens showed that chronic cholecystitis was found in 2792 (81.6%), acute cholecystitis in 237 (6.9%), and cholesterolosis in 223 (6.5%) patients. Dysplasia was found in 5 (0.14%) patients, and gallbladder carcinoma was detected in 4 (0.11%) patients. All patients with gallbladder carcinoma were diagnosed either preoperatively or intraoperatively, and none of the patients with gallbladder carcinoma were diagnosed from the histopathological examination. Conclusion: A strategy of selective approach for histopathological examination of gallbladder specimens may be safe in areas with very low incidence of gallbladder carcinoma. Such selective strategy is more cost-effective, reduces the workload of pathologists, and does not appear to compromise patient outcome.
Carcinoizii cu celule goblet (GCC) sunt tumori neuroendocrine extrem de rare şi sunt caracterizate prin combinaţia lor unică de două tipuri de celule canceroase -neuroendocrine (carcinoide) şi epiteliale (adenocarcinom). În ciuda faptului că GCC este considerată tumoră neuro-endocrină (NET), nu prezintă sindromul carcinoid ilicit. GCC apare de obicei în anexă şi reprezintă mai puţin de 14% din toate tumorile apendiceale. GCC extraapendiceal primar a fost raportat la stomac, duoden, intestinul subţire, colon şi rect. Lucrarea prezintă un caz rar de GCC a colonului ascendent la un bărbat de 57 de ani.Cuvinte cheie: carcinoid cu celule goblet, tumori neuroendocrine, glandă apocrină, celule care prezintă antigen
Epidermal cysts are a common benign skin abnormality, comprising 85-90% of all excised skin cysts. The term epidermal inclusion cyst refers specifically when the cyst resulted from the implantation of epidermal elements in the dermis. Squamous cell carcinomas (SCCs) are common skin lesions; however, a malignant transformation of an epidermal cyst is very rare with incidence of 0.011-0.045%. Few cases of malignant transformation of an epidermal cyst have been reported in the literature so far. This paper presents a case of squamous cell carcinoma arising from a scrotal epidermal cyst.
Majoritatea leziunilor mamare maligne sunt tumori primare, cu originea în ţesutul mamar. Cancerele mamare primare metastazează de regulă în ganglionii limfatici, plămâni, oase şi creier. Metastazele în sân din cancere ale altor organe sunt foarte rare, dar au fost întâlnite la pacienţi cu melanom malign, tumori carcinoide sau carcinom pulmonar. Prezentul articol raportează un caz de metastază mamară din melanom malign.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.